171 related articles for article (PubMed ID: 27318262)
21. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
Kovtun KA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Cancer; 2016 Dec; 122(23):3608-3614. PubMed ID: 27490845
[TBL] [Abstract][Full Text] [Related]
22. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
[TBL] [Abstract][Full Text] [Related]
23. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
24. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
Chen DY; See LC; Liu JR; Chuang CK; Pang ST; Hsieh IC; Wen MS; Chen TH; Lin YC; Liaw CC; Hsu CL; Chang JW; Kuo CF; Huang WK
J Clin Oncol; 2017 Nov; 35(32):3697-3705. PubMed ID: 28968166
[TBL] [Abstract][Full Text] [Related]
25. Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia.
Hicks BM; Yin H; Bladou F; Ernst P; Azoulay L
Thorax; 2017 Jul; 72(7):596-597. PubMed ID: 27986803
[TBL] [Abstract][Full Text] [Related]
26. Androgen deprivation therapy and the risk of iron-deficiency anaemia among patients with prostate cancer: a population-based cohort study.
Wu FJ; Li IH; Chien WC; Shih JH; Lin YC; Chuang CM; Cheng YD; Kao LT
BMJ Open; 2020 Mar; 10(3):e034202. PubMed ID: 32213519
[TBL] [Abstract][Full Text] [Related]
27. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study.
Jhan JH; Yeh HC; Chang YH; Guu SJ; Wu WJ; Chou YH; Li CC
J Diabetes Complications; 2018 Jul; 32(7):688-692. PubMed ID: 29909141
[TBL] [Abstract][Full Text] [Related]
28. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
29. Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
Liu R; Zhou J; Xia S; Li T
Urol Int; 2020; 104(3-4):214-221. PubMed ID: 31747673
[TBL] [Abstract][Full Text] [Related]
30. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
32. Use of androgen deprivation therapy for metastatic prostate cancer in older men.
Keating NL; O'Malley AJ; McNaughton-Collins M; Oh WK; Smith MR
BJU Int; 2008 May; 101(9):1077-83. PubMed ID: 18190632
[TBL] [Abstract][Full Text] [Related]
33. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
Thomsen FB; Sandin F; Garmo H; Lissbrant IF; Ahlgren G; Van Hemelrijck M; Adolfsson J; Robinson D; Stattin P
Eur Urol; 2017 Dec; 72(6):920-928. PubMed ID: 28711383
[TBL] [Abstract][Full Text] [Related]
34. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.
Mikkelsen MK; Thomsen FB; Berg KD; Jarden M; Larsen SB; Hansen RB; Brasso K
Scand J Urol; 2017 Dec; 51(6):464-469. PubMed ID: 28831860
[TBL] [Abstract][Full Text] [Related]
35. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
Wang Y; Dai B; Ye DW
Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
[TBL] [Abstract][Full Text] [Related]
36. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.
Schmid M; Sammon JD; Reznor G; Kapoor V; Speed JM; Abdollah FA; Sood A; Chun FK; Kibel AS; Menon M; Fisch M; Sun M; Trinh QD
BJU Int; 2016 Aug; 118(2):221-9. PubMed ID: 26074405
[TBL] [Abstract][Full Text] [Related]
37. Subsequent risk of acute urinary retention and androgen deprivation therapy in patients with prostate cancer: A population-based retrospective cohort study.
Yang TK; Wu CC; Chang CH; Muo CH; Huang CY; Chung CJ
Medicine (Baltimore); 2020 Feb; 99(7):e18842. PubMed ID: 32049786
[TBL] [Abstract][Full Text] [Related]
38. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
[TBL] [Abstract][Full Text] [Related]
39. Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania.
Drevinskaite M; Patasius A; Kincius M; Urbonas V; Smailyte G
BMJ Open; 2021 Jul; 11(7):e045797. PubMed ID: 34321292
[TBL] [Abstract][Full Text] [Related]
40. Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
Lee CH; Huang G; Chan PH; Hai J; Yeung CY; Fong CH; Woo YC; Ho KL; Yiu MK; Leung F; Lau TW; Tse HF; Lam KS; Siu CW
PLoS One; 2017; 12(2):e0171495. PubMed ID: 28158241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
